What question did this study set out to answer?

To determine if hemoadsorption with HA-330 reduces 28-day mortality in septic shock patients on high-dose norepinephrine.

June 13, 2026Critical CareOpen Access

HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE)

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial assesses mortality impact of hemoadsorption in septic shock patients, indicating potential treatment insights.

To determine if hemoadsorption with HA-330 reduces 28-day mortality in septic shock patients on high-dose norepinephrine.
Multicenter randomized controlled trial at two tertiary care centers in Thailand.
Patients with septic shock requiring norepinephrine ≥ 0.2 mcg/kg/min were randomized 1:1 to standard treatment or treatment with HA-330 hemoadsorption.
Trial terminated early due to slow recruitment, enrolling a total of 128 participants.
In the ST group, 38 of 65 (58%) patients died, compared to 28 of 63 (44%) in the HA group (relative risk 0.76; 95% CI, 0.54–1.07; P = 0.16).
Post-hoc analysis showed adjusted hazard ratio for mortality was 0.62 (95% CI, 0.39–0.97; P = 0.037).
No significant differences in organ support-free days, shock reversal, vasopressor doses, or inflammatory markers.

Wongtirawit et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark